Abstract
The increased formation of glycated proteins (advanced glycation end products (AGE’s)) is a possible mechanism to explain the increased risk of cardiovascular diseases with diabetes. Although earlier (animal) experimental studies have shown this role of AGE’s, research for this dissertation does not establish a connection between AGE’s in the blood and cardiovascular diseases in persons with diabetes type 2. Moreover, there is no definite epidemiologic proof for favourable effects of specific AGE-inhibiting treatments and for decreasing AGE’s in blood by existing treatments. This does not mean that AGE’s are unimportant in the development of diabetes 2 related cardiovascular diseases, but it does mean that the current biomarkers in blood don’t sufficiently reflect damage in tissues as a result of AGE’s. Better biomarkers are therefore needed.
| Original language | English |
|---|---|
| Qualification | Doctor of Philosophy |
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 12 Oct 2012 |
| Place of Publication | Maastricht |
| Publisher | |
| Print ISBNs | 978 94 6191 421 7 |
| DOIs | |
| Publication status | Published - 1 Jan 2012 |
Keywords
- cardiovascular diseases
- diabetes type 2
- glycated proteins
- biomarkers
Fingerprint
Dive into the research topics of 'The glycation pathway in type 2 diabetes and cardiovascular disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver